CCL26: A protein involved in many cellular processes and potential drug target

Target Name: CCL26

NCBI ID: G10344

CCL26

CCL26: A protein involved in many cellular processes and potential drug target

CCL26 (MIP-4alpha) is a protein that is expressed in various tissues throughout the body, including the lungs, heart, liver, and brain. It is a member of the MIP family of cytoskeletal proteins, which are involved in the regulation of cell shape and movement.

CCL26 is known for its role in the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to tissues. This is important for many diseases, including cancer, where new blood vessels can help to promote tumor growth.

One of the key functions of CCL26 is its ability to regulate the formation of blood vessels in the lungs. The lungs are responsible for filtering out the air we breathe, and they need to be able to adapt quickly to changing conditions in the environment. This is achieved through the regulation of the size and shape of the air sacs, which are surrounded by the blood vessels that supply them.

CCL26 plays a key role in this process by controlling the amount of cell death that occurs in the lungs. When the body is faced with a threat, such as the presence of a pathogen or an injury, the immune system sends a response by activating the lungs to fight off the invading agent. This involves the formation of new blood vessels in the lungs, which allows for increased oxygen and nutrient delivery to the affected area.

In addition to its role in angiogenesis, CCL26 is also involved in the regulation of the immune response. The immune system is essential for protecting the body against infection and disease, but it can sometimes cause damage to healthy cells. CCL26 helps to regulate the formation of immune cells in the body, and it has been shown to have anti-inflammatory effects.

CCL26 is also involved in the regulation of cell signaling, which is the process by which cells communicate with one another to coordinate their activities. This is important for many cellular processes, including cell division and the regulation of gene expression.

As a potential drug target, CCL26 is an attractive target for researchers because of its involvement in so many important cellular processes. Many studies have shown that blocking the activity of CCL26 has a variety of potential therapeutic effects, including the inhibition of cancer growth and the regulation of autoimmune diseases.

In addition to its potential therapeutic uses, CCL26 is also an important biomarker for many diseases. The levels of CCL26 in the body can be affected by a variety of factors, including inflammation, infection, and injury. Therefore, measuring the levels of CCL26 in the body can be a useful diagnostic tool for many diseases.

Overall, CCL26 is a protein that plays a critical role in many cellular processes throughout the body. Its involvement in angiogenesis, immune response, and cell signaling makes it an attractive target for drug development. Furthermore, its potential as a biomarker for many diseases makes it an important tool for the diagnosis and treatment of a wide range of conditions.

Protein Name: C-C Motif Chemokine Ligand 26

Functions: Chemoattractant for eosinophils and basophils (PubMed:10415065, PubMed:10488147). Acts as a ligand for C-C chemokine receptor CCR3 which triggers Ca(2+) mobilization in eosinophils (PubMed:10415065, PubMed:10488147, PubMed:11425309). Also acts as a ligand for CX3C chemokine receptor CX3CR1, inducing cell chemotaxis (PubMed:20974991)

The "CCL26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets